Novo Nordisk A/S has been upgraded to a Strong Buy rating following robust third-quarter results and accelerating adoption of its Wegovy pill. The stock trades at a low valuation compared to pharma peers, supporting a value-driven investment case. Analysts project annualized returns exceeding 18% through 2030, driven by expanding market share in oral GLP-1 drugs and a strong product pipeline. Risks include competition from Eli Lilly and potential delays in valuation growth, but these are considered priced in by the market.
As of Nov 06, 2026 18:31 WIB, Novo Nordisk (NVO) trades at USD 40.08, closer to its 52-week low of USD 35.29 than its high of USD 63.98, showing a significant discount despite the strong buy rating. The stock's dividend yield stands at 4.46%, and Pluang order activity heavily favors buying at 98%, indicating strong investor interest even as the price is down 0.55% on the day. This contrasts with its high valuation multiples noted in the article, highlighting a potential value opportunity on Pluang.
Novo Nordisk's stock rose 6.32% after Q3 results showed the Wegovy oral pill took about 80% of new obesity drug prescriptions in the US, surpassing expectations despite price cuts and competition. The pill's rapid adoption is driving volume growth, o...
Novo Nordisk reported strong Q3 results with revenue growth driven by its obesity care, especially the Wegovy pill, offsetting declines in diabetes products. International markets outperformed the U.S., and the company achieved a 40.1% adjusted opera...
Novo Resources announced a ~2,700 meter reverse circulation drilling program at its Tibooburra Gold Project in New South Wales, starting early November 2026. This follows recent surface sampling and mapping, with assays pending. The company is also r...
